Drug name - Tudorza Pressair

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(2 years from now)

CN1824664A ASTRAZENECA M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use
Jul, 2020

(2 years ago)

CN1373760A ASTRAZENECA M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use
Jul, 2020

(2 years ago)

CN100451018C ASTRAZENECA M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use
Jul, 2020

(2 years ago)

CN1272334C ASTRAZENECA M3 As Muscarinic Receptor Ligands Quinuclidine Derivatives And Their Use
Jul, 2020

(2 years ago)

IN200200049P1 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptor Ligands
Jul, 2020

(2 years ago)

IN224375B ASTRAZENECA A Quaternary Quinuclidine Compound Of Formula (I) And Process For Preparing The Same
Jul, 2020

(2 years ago)

EP1200431BA ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptor Ligands
Jul, 2025

(2 years from now)

EP1200431A2 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

EP1200431B3 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

EP1200431B1 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler Apr, 2027

(4 years from now)

US10085974 ASTRAZENECA Dosage and formulation Mar, 2029

(6 years from now)

US11000517 ASTRAZENECA Dosage and formulation Mar, 2029

(6 years from now)

Drugs and Companies using ACLIDINIUM BROMIDE ingredient

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.4MG/INH POWDER, METERED;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.